SMO and osteosarcoma: The functional importance of Hh signalling in osteosarcoma is highlighted in preclinical studies in which pathway activation is inhibited at the level of SMO or GLI, leading to reduced osteosarcoma cell growth in vitro and tumour growth in in vivo xenograft models [95, 104].